Abstract
Objective: A “window of opportunity” study in newly diagnosed ovarian (OV) and endometrial (EM) carcinoma patients was conducted to assess changes in PD-L1 expression and immune cell recruitment in response to pembrolizumab, a PD-1 inhibitor.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
